Time: 11:00 pm PST
January 28th 8:00am CET | 4:00pm JST | Jan, 27th 11:00pm PST
Dr Nuyttens will share his 15 years of experience in treating lung lesions with the CyberKnife System. He will focus on how effectively central lung tumors can be treated, the challenges faced and how he manages to deliver the most effective dose. Dr Nuyttens will show actual cases, planning, dose constraints and clinical outcomes.
Joost Nuyttens, M.D., Ph.D., Erasmus MC Cancer Institute, Rotterdam, the Netherlands
Dr. Nuyttens has been working in the Department of Radiation Oncology at Erasmus MC since 2001 and is currently an assistant professor in radiation oncology and director of the CyberKnife program. His focus is on thoracic and digestive cancer. He has published more than 100 publications in international journals, 5 book chapters on stereotactic radiotherapy for lung tumors and 1 on intra-operative brachytherapy. In the last 15 years, Dr. Nuyttens has been using the CyberKnife® System to treat early stage NSCLC, oligometastasis, and pancreatic cancer. He is also a project member of the Holland Proton Therapy Center in Delft.
In 1996, Dr Nuyttens graduated from the Medical School at Ghent University in Belgium where he also did his post-graduate medical specialty training in radiotherapy. He completed his education with advanced Radiation Oncology training at the Medical University of South Carolina (USA) and was a research fellow at the William Beaumont Hospital in Detroit (USA).
Moderated by: Hiroshi Onishi, M.D., Ph.D., University of Yamanashi, Japan
Professor Hiroshi Onishi was appointed Professor and Chairman of the Department of Radiology at the University of Yamanashi in 2014. He specializes in stereotactic body radiotherapy (SBRT), particularly for lung cancer. He first showed the minimum required dose of SBRT for stage I non-small cell lung cancer (NSCLC), and his papers have been cited in the NCCN guideline for NSCLC. He developed a respiratory monitoring device, named “Abches” that simply and easily achieves good reproducibility of voluntary patient breath-holding and is used in more than 300 radiotherapy facilities in Japan.